Overview of current detection methods and microRNA potential in Clostridioides difficile infection screening  

作　　者：Marco Bocchetti Maria Grazia Ferraro Federica Melisi Piera Grisolia Marianna Scrima Alessia Maria Cossu Tung On Yau 

机构地区：[1]Department of Precision Medicine,University of Campania“Luigi Vanvitelli,”Naples 80138,Italy [2]Department of Molecular Oncology,Precision Medicine Laboratory and COVID19 Laboratory,Biogem Scarl,Ariano Irpino 83031,Italy [3]School of Infection and Immunity,College of Medical Veterinary and Life Sciences,University of Glasgow,Glasgow G128QQ,United Kingdom [4]Department of Pharmacy,School of Medicine and Surgery,University of Naples“Federico Ⅱ,”Naples 80131,Italy [5]School of Science and Technology,Nottingham Trent University,Nottingham NG118NS,United Kingdom [6]Department of Rural Land Use,Scotland’s Rural College,Aberdeen AB219YA,Scotland,United Kingdom [7]Department of Health Science,University of the People,Pasadena,CA 9110112,United States

出　　处：《World Journal of Gastroenterology》2023年第22期3385-3399,共15页世界胃肠病学杂志（英文版）

摘　　要：Clostridioides difficile(formerly called Clostridium difficile,C.difficile)infection(CDI)is listed as an urgent threat on the 2019 antibiotic resistance threats report in the United States by the Centers for Disease Control and Prevention.Early detection and appropriate disease management appear to be essential.Meanwhile,although the majority of cases are hospital-acquired CDI,community-acquired CDI cases are also on the rise,and this vulnerability is not limited to immunocompromised patients.Gastrointestinal treatments and/or gastrointestinal tract surgeries may be required for patients diagnosed with digestive diseases.Such treatments could suppress or interfere with the patient’s immune system and disrupt gut flora homeostasis,creating a suitable microecosystem for C.difficile overgrowth.Currently,stool-based non-invasive screening is the first-line approach to CDI diagnosis,but the accuracy is varied due to different clinical microbiology detection methods;therefore,improving reliability is clearly required.In this review,we briefly summarised the life cycle and toxicity of C.difficile,and we examined existing diagnostic approaches with an emphasis on novel biomarkers such as microRNAs.These biomarkers can be easily detected through noninvasive liquid biopsy and can yield crucial information about ongoing pathological phenomena,particularly in CDI.

关 键 词：Clostridioides difficile MICRORNA DIAGNOSTIC PROGNOSTIC BIOMARKER 

分 类 号：R446.5[医药卫生—诊断学]